Proactive Investors - Run By Investors For Investors

NetScientific portfolio companies Vortex Biosciences and Wanda to be wound up

NetScientific also announced that PDS and Edge Therapeutics have completed their all-share merger
NetScientific
NetScientific invests in development-stage medical and healthcare businesses

NetScientific PLC (LON:NSCI) said on Monday that its portfolio companies Vortex Biosciences and Wanda Inc are set to be wound up.

The firm, which invests in development-stage medical and healthcare businesses, had received an indicative proposal from a third party for the sale of its shareholdings in Vortex and Wanda.

READ: NetScientific expects shareholders to reject plan to delist from AIM and become private company

But after considering the indicative terms of the potential disposal and the expected timeline to complete a deal, NetScientific concluded that “the level of consideration offered is not sufficient to justify the company continuing to provide the necessary financial support to Wanda and Vortex” while it carries out due diligence and negotiations.

The group said such a move would affect the company’s ability to allocate sufficient cash resources to its other portfolio companies Glycotest Inc., ProAxsis Ltd and PDS BioTechnology. NetScientific believes these portfolio companies have the “most realistic prospects” of delivering shareholder returns.

“The board has therefore concluded that it was not in the best interests of the company to proceed with the potential disposal,” it said.

“Subsequently, the directors of Vortex and Wanda respectively resolved to effect the orderly wind up of those companies.”

In a separate announcement, NetScientific announced that PDS and Edge Therapeutics Inc. (NASDAQ:EDGE) have completed their all-share merger.

READ: NetScientific lifted as portfolio company PDS Biotechnology announces merger with Edge Therapeutics

The combined company will trade under the PDS name and will start trading on Nasdaq today under the ticker PDSB.

NetScientific's chief executive Francois Martelet said: "We are delighted that the merger has completed, and with the liquidity attributable to NetScientific's holding in PDS Biotechnology Corporation following the listing on Nasdaq."

View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

1538160791_petri-dishes.jpg
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use